Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is: Dose Escalation: • To assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination with cemiplimab Dose Expansion: • To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by objective response rate (ORR) per modified Prostate Cancer Working Group (PCWG3) criteria The secondary objectives of the study are: Dose Escalation: • To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by ORR per modified PCWG3 criteria Dose Expansion: - To characterize the safety profile in each expansion cohort - To characterize the PK of REGN4336 as monotherapy or in combination with cemiplimab In both Dose Escalation and Dose Expansion: - To assess preliminary anti-tumor activity of REGN4336 as monotherapy or in combination with cemiplimab as measured by prostate specific antigen (PSA) decline - To evaluate immunogenicity of REGN4336 in Module 1 and immunogenicity of REGN4336 and cemiplimab in Module 2


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05125016
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date November 19, 2021
Completion date August 4, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04986423 - ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1/Phase 2
Completed NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC Phase 2
Recruiting NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase 1/Phase 2
Recruiting NCT03230734 - Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05116579 - Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Active, not recruiting NCT03732820 - Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer Phase 3
Recruiting NCT05005728 - XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT04068896 - Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Phase 1/Phase 2
Recruiting NCT04509557 - [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. Phase 1
Active, not recruiting NCT04227275 - A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer Phase 1
Not yet recruiting NCT04754191 - Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT02744287 - Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT02861573 - Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Phase 1/Phase 2
Recruiting NCT03176381 - Tissue Predictors of Abiraterone Benefit
Recruiting NCT04629781 - Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC Phase 1
Completed NCT02111577 - Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer Phase 3
Completed NCT02116582 - A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer Phase 4
Active, not recruiting NCT02044354 - Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer Phase 3
Completed NCT02705469 - A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1